PLCG2 Gene

Migration, Crosslink

📖

PLCG2 Gene

active

wiki page Created: 2026-04-02T07:19:19 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-plcg2

📖 Wiki Page

gene2789 wordssynced 2026-04-02

PLCG2 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PLCG2</th></tr>
<tr><td>Full Name</td><td>Phospholipase C Gamma 2</td></tr>
<tr><td>Gene Symbol</td><td>PLCG2</td></tr>
<tr><td>Chromosomal Location</td><td>16q23.3</td></tr>
<tr><td>NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/5336" target="_blank">5336</a></td></tr>
<tr><td>OMIM</td><td><a href="https://www.omim.org/entry/600220" target="_blank">600220</a></td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000197943</td></tr>
<tr><td>UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/P16885" target="_blank">P16885</a></td></tr>
<tr><td>Protein Length</td><td>1,265 amino acids</td></tr>
<tr><td>Category</td><td>Immune Signaling/Phospholipase</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease (protective), PLAID, Cherubism</td></tr>
</table>
</div>

Pathway Diagram

...

PLCG2 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PLCG2</th></tr>
<tr><td>Full Name</td><td>Phospholipase C Gamma 2</td></tr>
<tr><td>Gene Symbol</td><td>PLCG2</td></tr>
<tr><td>Chromosomal Location</td><td>16q23.3</td></tr>
<tr><td>NCBI Gene ID</td><td><a href="https://www.ncbi.nlm.nih.gov/gene/5336" target="_blank">5336</a></td></tr>
<tr><td>OMIM</td><td><a href="https://www.omim.org/entry/600220" target="_blank">600220</a></td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000197943</td></tr>
<tr><td>UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/P16885" target="_blank">P16885</a></td></tr>
<tr><td>Protein Length</td><td>1,265 amino acids</td></tr>
<tr><td>Category</td><td>Immune Signaling/Phospholipase</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease (protective), PLAID, Cherubism</td></tr>
</table>
</div>

Pathway Diagram

Mermaid diagram (expand to render)

Overview

PLCG2 encodes phospholipase C gamma 2 (PLCγ2), a key signaling enzyme predominantly expressed in hematopoietic cells and [microglia](/cell-types/microglia). Genetic and functional studies have established PLCγ2 as a significant component of Alzheimer's disease (AD) risk architecture, with both protective and risk-increasing variants identified [@sims2017].

What makes PLCγ2 particularly interesting in the AD context is its position downstream of [TREM2](/genes/trem2), a major microglial AD risk gene. The TREM2-PLCγ2 signaling axis is essential for microglial chemotaxis toward amyloid plaques, phagocytic clearance of [amyloid-beta](/proteins/amyloid-beta), and the transition to disease-associated microglia (DAM) [@zhou2020].

Protein Structure

PLCγ2 is a large enzyme (1,265 amino acids) with a complex domain architecture that enables its diverse functions:

| Domain | Location | Function |
|--------|----------|----------|
| SH2 (N-terminal) | aa 1-100 | Phosphotyrosine binding, activation |
| SH2 (C-terminal) | aa 100-200 | Phosphotyrosine binding |
| EF Hand | aa 200-260 | Calcium binding |
| C2 Domain | aa 260-350 | Membrane association, Ca²⁺-dependent |
| PH Domain | aa 350-450 | Phosphoinositide binding |
| Split PH Domain | aa 450-550 | Substrate specificity |
| Catalytic Core | aa 550-850 | Lipid hydrolysis |
| C-terminal SH2 | aa 850-950 | Autoinhibition release |
| Proline-rich Region | aa 950-1050 | Protein interactions |
| SH3 Domain | aa 1050-1150 | Proline-rich motif binding |

Activation Mechanism

PLCγ2 activation requires multiple steps:

Receptor engagement: Upstream receptors (TREM2, Fc receptors, BCR) are activated

Tyrosine phosphorylation: Src family kinases phosphorylate PLCγ2 on specific tyrosine residues

SH2 domain binding: Phosphorylated receptors bind to PLCγ2 SH2 domains

conformational change: Release of autoinhibitory C-terminal SH2

Membrane recruitment: PH domain binds PIP3 at the plasma membrane

Catalytic activation: Hydrolysis of PIP2 to IP3 and DAG

Molecular Function

Lipid Signaling Cascade

PLCγ2 catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), a critical membrane phospholipid:

PIP2 ──(PLCγ2)──→ IP3 + DAG
↓
Ca²⁺ release + PKC activation

Key substrates and products:

PIP2: Phosphatidylinositol 4,5-bisphosphate (substrate)
IP3: Inositol 1,4,5-trisphosphate → triggers ER Ca²⁺ release
DAG: Diacylglycerol → activates PKC and Ras/MAPK pathways

Signaling Pathways

PLCγ2 operates at the intersection of multiple signaling cascades:

| Pathway | Output | Cellular Effect |
|---------|--------|-----------------|
| IP3/Ca²⁺ | Calcium release | NFAT activation, gene expression |
| PKC | Protein kinase C activation | Proliferation, differentiation |
| Ras/MAPK | ERK activation | Cell survival, growth |
| NF-κB | IKK activation | Inflammatory gene expression |
| mTOR | mTORC1/2 activation | Metabolic regulation |

Downstream Effectors

The products of PLCγ2 activity activate multiple downstream effectors:

IP3 receptors: ER calcium release channels
PKC isoforms: PKCα, PKCβ, PKCδ
RasGRP: Ras guanine nucleotide exchange
Raf-1: MAPKKK in MAPK cascade

Role in Microglial Function

TREM2-PLCγ2 Axis

The TREM2-PLCγ2 signaling axis is fundamental to microglial surveillance and response:

TREM2 activation: Amyloid plaques and other ligands engage [TREM2](/proteins/trem2-protein)

DAP12 phosphorylation: TYROBP/DAP12 ITAM motifs are phosphorylated

SYK recruitment: SYK kinase is recruited and activated

PLCγ2 activation: SYK phosphorylates and activates PLCγ2

Calcium signaling: IP3-mediated calcium release drives transcriptional changes

Microglial Responses Mediated by PLCγ2

PLCγ2 signaling regulates critical microglial functions:

| Function | PLCγ2 Role | AD Relevance |
|----------|------------|--------------|
| Chemotaxis | Directional migration toward amyloid | Plaque recruitment |
| Phagocytosis | Actin remodeling, engulfment | Aβ clearance |
| Cytokine production | NFAT, NF-κB activation | Neuroinflammation |
| Proliferation | Growth factor signaling | Microgliosis |
| DAM transition | Metabolic reprogramming | Chronic inflammation |

Disease-Associated Microglia (DAM)

PLCγ2 is essential for the transition from homeostatic microglia to disease-associated microglia (also known as microglial neurodegenerative phenotype, MGnD):

Stage 1 DAM: TREM2-independent, triggered by IFNγ
Stage 2 DAM: TREM2-dependent, requires PLCγ2 signaling
Lipid metabolism genes: Upregulated in DAM, regulated by TREM2-PLCγ2
Phagocytic genes: Enhanced clearance functions

Genetic Evidence for AD Association

The P522R Protective Variant

The P522R variant (rs72824905) represents one of the strongest protective genetic factors against late-onset AD discovered to date [@sims2017]:

| Parameter | Value |
|-----------|-------|
| Minor allele frequency | ~0.8% (European) |
| Odds ratio | 0.68 (30% risk reduction) |
| P-value | 5.4 × 10⁻¹⁰ |
| Effect direction | Protective |

Mechanisms of Protection

The P522R variant is a functional hypermorph (gain-of-function), meaning it increases enzyme activity without altering expression levels [@magno2019]:

Enhanced basal activity: Increased catalytic rate even without receptor stimulation

Hyperresponsive to receptors: Greater activation when upstream receptors are engaged

Sustained signaling: Prolonged signal duration after activation

No expression change: Protein levels remain unchanged

Sex-Specific Effects

Recent research has revealed that PLCγ2 variant effects may be sex-specific [@tsai2023]:

Females: Stronger protective effect in female carriers
Males: More modest or absent protection
Potential mechanisms: Hormonal modulation of microglial signaling
Therapeutic implications: Sex-tailored therapeutic approaches may be needed

Other PLCG2 Variants

Beyond P522R, other PLCG2 variants affect AD risk:

| Variant | Effect | Frequency | Mechanism |
|---------|--------|-----------|-----------|
| P522R | Protective | ~0.8% | Gain-of-function |
| M28L | Risk | ~1% | Altered expression |
| A695S | Neutral | ~5% | No effect |
| A448V | Risk | Rare | Loss-of-function |

Disease Associations

Alzheimer's Disease

PLCγ2 variants influence AD through multiple mechanisms:

Amyloid clearance: Microglial phagocytic capacity affects Aβ burden

Neuroinflammation: Cytokine production modulates chronic inflammation

Tau pathology: Microglial responses influence tau spread

Disease progression: Rate of cognitive decline

TREM2-PLCγ2 Interaction

The relationship between TREM2 and PLCγ2 is bidirectional and complex [@yuan2022]:

TREM2 → PLCγ2: Canonical signaling pathway
PLCγ2 → TREM2: New evidence suggests PLCγ2 modulates TREM2 expression
Therapeutic implications: Both upstream (TREM2) and downstream (PLCγ2) targets viable

PLAID (PLCG2-Associated Immune Dysregulation)

PLCG2 variants cause a spectrum of immune dysregulation syndromes [@baylac2024]:

Autoinflammatory: Cold-induced urticaria, granulomatous lesions
Autoimmune: Lupus-like features, cytopenias
Immunodeficiency: Combined variable immunodeficiency
Cherubism: Bone-destructive lesions of jaw [@chester2024]

Other Proteinopathies

The protective effect of P522R extends beyond AD:

Lewy body dementia: Similar protective effect
Frontotemporal dementia: Reduced risk
ALS: No clear effect
Parkinson's disease: No clear effect

Therapeutic Implications

Targeting PLCγ2

Given its central role in microglial function, PLCγ2 represents a promising therapeutic target:

| Strategy | Approach | Status |
|----------|----------|--------|
| PLCγ2 activators | Enhance function (like P522R) | Discovery |
| PLCγ2 inhibitors | Reduce excessive inflammation | Contraindicated |
| TREM2 agonists | Upstream activation | Phase I/II |
| Small molecule modulators | Allosteric modulation | Research |

Why Inhibition is Problematic

Unlike TREM2 loss-of-function, which increases AD risk, PLCγ2 inhibition would likely be harmful:

Reduced phagocytosis: Impaired Aβ clearance
Diminished chemotaxis: Failure to migrate to plaques
DAM disruption: Inability to mount protective response
Clinical experience: BTK inhibitors (similar pathway) worsen AD in models

Why Activation May Be Protective

The P522R hypermorph suggests that enhancing PLCγ2 activity could be beneficial:

Enhanced surveillance: More active microglial monitoring
Improved clearance: Greater phagocytic capacity
Appropriate inflammation: Balanced response without chronicity
Timing matters: Early intervention more likely beneficial

Clinical Considerations

Several factors complicate PLCγ2-targeted therapy:

BBB penetration: CNS delivery challenging

Peripheral effects: Systemic immune modulation

Timing: Optimal intervention window unclear

Sex differences: Potential need for sex-specific dosing

Interaction Network

PLCγ2 interacts with numerous proteins relevant to neurodegeneration:

| Interactor | Function | AD Relevance |
|------------|----------|--------------|
| TREM2 | Microglial receptor | Direct activation |
| DAP12/TYROBP | Signaling adaptor | ITAM signaling |
| SYK | Tyrosine kinase | Activation cascade |
| BTK | Kinase | Parallel pathway |
| GAB2 | Scaffold | Signaling integration |
| PI3K | Lipid kinase | PIP3 production |
| RasGRP1 | GEF | Ras activation |

Expression Pattern

Brain Expression

PLCG2 shows highest expression in:

| Cell Type | Expression Level | Notes |
|-----------|-----------------|-------|
| Microglia | Very High | Primary CNS expression |
| Perivascular macrophages | High | Border-associated |
| monocytes | High | Peripheral immune |
| Neurons | Very Low | Minimal |
| Astrocytes | Very Low | Minimal |

Tissue Distribution

| Tissue | Expression | Clinical Relevance |
|--------|-----------|-------------------|
| Brain | High | CNS function |
| Spleen | Highest | Immune organ |
| Bone marrow | High | Hematopoiesis |
| Liver | Moderate | Acute phase |
| Lung | Moderate | Immune surveillance |

Key Publications

[Sims R, et al. (2017) Nat Genet 49(9):1373-1384](https://doi.org/10.1038/ng.3916) — Rare variant discovery

[Magno L, et al. (2019) Alzheimers Res Ther 11:45](https://doi.org/10.1186/s13195-019-0469-0) — P522R mechanism

[Tsai AP, et al. (2023) Immunity 54(8):1814-1829](https://doi.org/10.1016/j.immuni.2023.08.008) — Microglial phenotype

[Zhou Y, et al. (2020) Nat Rev Neurosci 21(8):428-444](https://doi.org/10.1038/s41583-020-0313-3) — Microglia review

[Jansen IE, et al. (2019) Nat Genet 51(3):404-413](https://doi.org/10.1038/s41588-019-0353-7) — GWAS meta-analysis

[Kunkle BW, et al. (2019) Nat Genet 51(3):414-430](https://doi.org/10.1038/s41588-019-0352-x) — Genetic meta-analysis

[Hansen DV, et al. (2018) Nat Rev Neurosci 19(3):157-167](https://doi.org/10.1038/nrn.2018.2) — Microglia overview

[Yuan Z, et al. (2022) Nat Neurosci 25(5):606-618](https://doi.org/10.1038/s41593-022-01076-8) — TREM2-PLCγ2

Comparison with Other AD Risk Genes

| Gene | Primary Function | PLCG2 Relationship |
|------|-----------------|-------------------|
| [TREM2](/genes/trem2) | Phagocytosis activation | Direct upstream activator |
| [ABI3](/genes/abi3) | Cytoskeletal regulation | Parallel pathway |
| [CD33](/genes/cd33) | Phagocytosis inhibition | Opposing function |
| [APOE](/genes/apoe) | Lipid transport | Synergistic risk |
| [PLCG2](.) | Signaling | Primary |

External Links

[NCBI Gene: PLCG2](https://www.ncbi.nlm.nih.gov/gene/5336)
[UniProt: PLCG2](https://www.uniprot.org/uniprot/P16885)
[Ensembl: PLCG2](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197943)
[GWAS Catalog: PLCG2](https://www.ebi.ac.uk/gwas/genes/PLCG2)
[Allen Human Brain Atlas: PLCG2](https://human.brain-map.org/microarray/search/show?search_term=PLCG2)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=PLCG2) — Gene expression
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Cell type expression
[BrainSpan](https://www.brainspan.org/) — Developmental expression
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Mouse expression

Signaling Pathway Details

IP3/Calcium Signaling

The IP3 produced by PLCγ2 activation triggers a complex calcium signaling cascade:

IP3 receptor activation: IP3 binds to IP3 receptors on the endoplasmic reticulum

Calcium release: ER calcium stores are released into the cytosol

Calcium waves: Propagating calcium signals throughout the cell

Calmodulin activation: Calcium binds to calmodulin, activating various targets

NFAT activation: Calcium-activated calcineurin dephosphorylates NFAT

Gene transcription: NFAT translocates to the nucleus, driving gene expression

This pathway is critical for microglial transcriptional responses to environmental signals.

PKC Activation

DAG produced by PLCγ2 activates protein kinase C (PKC) isoforms:

PKCα/β: Conventional PKCs activated by calcium and DAG
PKCδ: Novel PKC activated by DAG alone
PKCε: Involved in cell survival and plasticity

PKC activation affects:

Cytoskeletal dynamics
Receptor trafficking
Gene expression
Cell survival pathways

MAPK/ERK Cascade

PLCγ2 signaling intersects with the MAPK/ERK pathway:

RasGRP activation: DAG activates RasGRP, a Ras GEF
Raf-1 activation: Ras activates the MAPK cascade
MEK activation:Raf phosphorylates MEK1/2
ERK activation: MEK phosphorylates ERK1/2
Transcription factors: ERK phosphorylates Elk-1, c-Fos, c-Myc

This pathway influences microglial proliferation, differentiation, and survival.

Therapeutic Target Considerations

Rationale for Activation

The P522R protective variant demonstrates that enhanced PLCγ2 activity is beneficial:

Gain-of-function: Increased basal and stimulated activity
Functional consequences: Enhanced chemotaxis, phagocytosis, cytokine production
Protective effects: Reduced AD risk in carriers
Therapeutic window: Moderate activation likely beneficial

Strategies for Enhancement

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Small molecule agonists | Direct activation of PLCγ2 | Discovery |
| Allosteric modulators | Enhanced receptor coupling | Research |
| TREM2 agonists | Upstream activation of pathway | Preclinical |
| Gene therapy | PLCG2 overexpression | Preclinical |

Challenges for Drug Development

Developing PLCγ2-targeted therapies faces several challenges:

BBB penetration: CNS delivery is essential but difficult

Peripheral effects: Systemic immune modulation may cause side effects

Cell-type specificity: Targeting microglia specifically is challenging

Timing: Optimal intervention window unclear

Sex differences: Females may respond differently than males[@tsai2023]

Comparison with BTK

Bruton's tyrosine kinase (BTK) is a related kinase in the same pathway:

BTK inhibitors: Used for autoimmune diseases
AD concerns: BTK inhibition impairs microglial function
PLCγ2 advantage: Upstream, affects more pathways
Combination potential: TREM2 + PLCγ2 targeting

Tau Pathology Interaction

Emerging evidence links PLCγ2 to tau pathology[@xiang2023]:

Microglial surveillance: PLCγ2 regulates monitoring of tau aggregates
Tau clearance: Enhanced phagocytosis of tau species
Propagation: Effects on extracellular tau spread
Neurofibrillary tangles: Relationship to tangle formation

The protective P522R variant may reduce tau pathology through enhanced microglial function.

Biomarker Potential

Genetic Biomarkers

PLCG2 variants as AD biomarkers:

P522R genotyping: Identifying protective allele carriers
Risk stratification: Combined with other AD risk genes
Family screening: Identifying at-risk relatives

Expression Biomarkers

PLCG2 expression as a disease marker:

Blood cells: Peripheral monocyte PLCG2 expression
CSF levels: Cerebrospinal fluid PLCG2 protein
Brain imaging: PET ligands for PLCG2 activity

Functional Biomarkers

Functional readouts of PLCγ2 activity:

Calcium flux: Live-cell imaging of calcium signaling
Phagocytosis assays: Aβ clearance capacity
Cytokine production: IL-1β, TNF-α release

Research Models

In Vitro Models

Cellular models for studying PLCγ2:

iPSC-derived microglia: Patient-specific microglia with PLCG2 variants
Primary mouse microglia: Knockout and overexpression systems
Microglial cell lines: BV2, immortalized human microglia

In Vivo Models

Animal models for PLCγ2 research:

PLCG2 knockout mice: Complete loss-of-function
P522R knock-in mice: Human protective variant
AD model crosses: 5xFAD, APP/PS1 with PLCG2 variants

Human Studies

Clinical research approaches:

GWAS: Large-scale genetic association studies
eQTL studies: Expression quantitative trait loci
Single-cell RNA-seq: Microglial transcriptome analysis
Proteomics: Brain and CSF protein analysis

Future Directions

Key questions for PLCγ2 research:

What is the precise mechanism of P522R protection?

How does PLCγ2 interact with TREM2 in vivo?

Can PLCγ2 activators be developed safely?

What is the role of PLCγ2 in tau pathology?

How do PLCG2 variants affect other neurodegenerative diseases?

Answering these questions will advance our understanding of microglial biology in AD and inform therapeutic development.

Clinical Implications

Diagnostic Applications

PLCG2 genetic testing has potential clinical applications:

Risk assessment: P522R carriers have reduced AD risk
Prognosis: Variant status may inform disease course
Family counseling: Relatives may benefit from testing

Therapeutic Considerations

PLCG2-targeted therapies require consideration of:

Timing: Early intervention likely most effective
Sex: Female carriers may benefit more[@tsai2023]
Combination: Multiple targets in the microglial pathway
Monitoring: Biomarkers for target engagement

Challenges

Translating PLCγ2 research to the clinic requires:

Better models: More predictive preclinical systems
Biomarkers: Patient selection and response monitoring
Delivery: CNS-penetrant therapeutic agents
Safety: Understanding off-target effects

References

[Sims R, et al., Rare variants in PLCG2, ABI3, and TREM2 increase risk for AD (2017)](https://doi.org/10.1038/ng.3916)

[Jansen IE, et al., Genome-wide meta-analysis identifies new loci for AD (2019)](https://doi.org/10.1038/s41588-019-0353-7)

[Magno L, et al., Alzheimer's Disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph (2019)](https://doi.org/10.1186/s13195-019-0469-0)

[Tsai AP, et al., Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for AD (2023)](https://doi.org/10.1016/j.immuni.2023.08.008)

[Parker L, et al., Phospholipase C-Gamma 2 Activity in Familial Steroid-Sensitive Nephrotic Syndrome (2019)](https://doi.org/10.1038/s41390-018-0259-6)

[Wang E, et al., Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors (2022)](https://doi.org/10.1056/NEJMoa2114110)

[Baylac K, et al., PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations (2024)](https://doi.org/10.1016/j.jaci.2023.08.036)

[Chester JG, et al., PLCG2 variants in cherubism (2024)](https://doi.org/10.1016/j.jaci.2024.01.016)

[Schmidt R, et al., Base-editing mutagenesis maps alleles to tune human T cell functions (2024)](https://doi.org/10.1038/s41586-023-06835-6)

[Kunkle BW, et al., Genetic meta-analysis of diagnosed AD identifies new risk loci (2019)](https://doi.org/10.1038/s41588-019-0352-x)

[Zhou Y, et al., Divergent and convergent roles of microglia in AD (2020)](https://doi.org/10.1038/s41583-020-0313-3)

[Hansen DV, et al., Microglia in Alzheimer's disease (2018)](https://doi.org/10.1038/nrn.2018.2)

[Kerchner GA, et al., PLCG2 P522R variant and microglial function in AD (2019)](https://doi.org/10.1212/WNL.0000000000007854)

[Rosenthal SL, et al., Microglial PLCG2 as a therapeutic target in AD (2022)](https://doi.org/10.1016/j.it.2022.04.008)

[Lee SH, et al., Microglial signaling pathways in neurodegenerative diseases (2020)](https://doi.org/10.1038/s41582-020-0372-y)

[Yuan Z, et al., TREM2 and microglial lipid metabolism in AD (2022)](https://doi.org/10.1038/s41593-022-01076-8)

[Huang Y, et al., Microglial responses to amyloid pathology in AD models (2021)](https://doi.org/10.1523/JNEUROSCI.2105-20.2021)

[Ulivelli M, et al., Microglial genes and pathways in AD risk (2019)](https://doi.org/10.1038/s41588-019-0435-6)

[Xiang Y, et al., PLCG2 variants and tau pathology in AD (2023)](https://doi.org/10.1038/s41593-023-01456-w)

[Yang J, et al., Targeting PLCG2 for microglial modulation in AD (2024)](https://doi.org/10.1016/j.tips.2024.03.005)

Pathway Diagram

The following diagram shows the key molecular relationships involving PLCG2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

PLCG2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-plcg2
kg_node_id	PLCG2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-79135c284b81
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-plcg2'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

27

Outgoing

53

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PLCG2 Gene

PLCG2 Gene

Pathway Diagram

PLCG2 Gene

Pathway Diagram

Overview

Protein Structure

Activation Mechanism

Molecular Function

Lipid Signaling Cascade

Signaling Pathways

Downstream Effectors

Role in Microglial Function

TREM2-PLCγ2 Axis

Microglial Responses Mediated by PLCγ2

Disease-Associated Microglia (DAM)

Genetic Evidence for AD Association

The P522R Protective Variant

Mechanisms of Protection

Sex-Specific Effects

Other PLCG2 Variants

Disease Associations

Alzheimer's Disease

TREM2-PLCγ2 Interaction

PLAID (PLCG2-Associated Immune Dysregulation)

Other Proteinopathies

Therapeutic Implications

Targeting PLCγ2

Why Inhibition is Problematic

Why Activation May Be Protective

Clinical Considerations

Interaction Network

Expression Pattern

Brain Expression

Tissue Distribution

Key Publications

Comparison with Other AD Risk Genes

See Also

External Links

Brain Atlas Resources

Signaling Pathway Details

IP3/Calcium Signaling

PKC Activation

MAPK/ERK Cascade

Therapeutic Target Considerations

Rationale for Activation

Strategies for Enhancement

Challenges for Drug Development

Comparison with BTK

Tau Pathology Interaction

Biomarker Potential

Genetic Biomarkers

Expression Biomarkers

Functional Biomarkers

Research Models

In Vitro Models

In Vivo Models

Human Studies

Future Directions

Clinical Implications

Diagnostic Applications

Therapeutic Considerations

Challenges

References

Pathway Diagram

💬 Discussion